TY - JOUR
T1 - Vaccines targeting tumor blood vessel antigens promote CD8 + T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice
AU - Zhao, Xi
AU - Bose, Anamika
AU - Komita, Hideo
AU - Taylor, Jennifer L.
AU - Chi, Nina
AU - Lowe, Devin B.
AU - Okada, Hideho
AU - Cao, Ying
AU - Mukhopadhyay, Debabrata
AU - Cohen, Peter A.
AU - Storkus, Walter J.
PY - 2012/2/15
Y1 - 2012/2/15
N2 - We have recently shown that effective cytokine gene therapy of solid tumors in HLA-A2 transgenic (HHD) mice lacking murine MHC class I molecule expression results in the generation of HLA-A2-restricted CD8 + T effector cells selectively recognizing tumor blood vessel-associated pericytes and/or vascular endothelial cells. Using an HHD model in which HLA-A2 neg tumor (MC38 colon carcinoma or B16 melanoma) cells are not recognized by the CD8 + T cell repertoire, we now show that vaccines on the basis of tumor-associated blood vessel Ags (TBVA) elicit protective Tc1-dependent immunity capable of mediating tumor regression or extending overall survival. Vaccine efficacy was not observed if (HLA-A2 neg) wild-type C57BL/6 mice were instead used as recipient animals. In the HHD model, effective vaccination resulted in profound infiltration of tumor lesions by CD8 + (but not CD4 +) T cells, in a coordinate reduction of CD31 + blood vessels in the tumor microenvironment, and in the "spreading" of CD8 +T cell responses to alternate TBVA that were not intrinsic to the vaccine. Protective Tc1-mediated immunity was durable and directly recognized pericytes and/or vascular endothelial cells flow-sorted from tumor tissue but not from tumor-uninvolved normal kidneys harvested from these same animals. Strikingly, the depletion of CD8 +, but not CD4 +, T cells at late time points after effective therapy frequently resulted in the recurrence of disease at the site of the regressed primary lesion. This suggests that the vaccine-induced anti-TBVA T cell repertoire can mediate the clinically preferred outcomes of either effectively eradicating tumors or policing a state of (occult) tumor dormancy.
AB - We have recently shown that effective cytokine gene therapy of solid tumors in HLA-A2 transgenic (HHD) mice lacking murine MHC class I molecule expression results in the generation of HLA-A2-restricted CD8 + T effector cells selectively recognizing tumor blood vessel-associated pericytes and/or vascular endothelial cells. Using an HHD model in which HLA-A2 neg tumor (MC38 colon carcinoma or B16 melanoma) cells are not recognized by the CD8 + T cell repertoire, we now show that vaccines on the basis of tumor-associated blood vessel Ags (TBVA) elicit protective Tc1-dependent immunity capable of mediating tumor regression or extending overall survival. Vaccine efficacy was not observed if (HLA-A2 neg) wild-type C57BL/6 mice were instead used as recipient animals. In the HHD model, effective vaccination resulted in profound infiltration of tumor lesions by CD8 + (but not CD4 +) T cells, in a coordinate reduction of CD31 + blood vessels in the tumor microenvironment, and in the "spreading" of CD8 +T cell responses to alternate TBVA that were not intrinsic to the vaccine. Protective Tc1-mediated immunity was durable and directly recognized pericytes and/or vascular endothelial cells flow-sorted from tumor tissue but not from tumor-uninvolved normal kidneys harvested from these same animals. Strikingly, the depletion of CD8 +, but not CD4 +, T cells at late time points after effective therapy frequently resulted in the recurrence of disease at the site of the regressed primary lesion. This suggests that the vaccine-induced anti-TBVA T cell repertoire can mediate the clinically preferred outcomes of either effectively eradicating tumors or policing a state of (occult) tumor dormancy.
UR - http://www.scopus.com/inward/record.url?scp=84863116270&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863116270&partnerID=8YFLogxK
U2 - 10.4049/jimmunol.1101644
DO - 10.4049/jimmunol.1101644
M3 - Article
C2 - 22246626
AN - SCOPUS:84863116270
SN - 0022-1767
VL - 188
SP - 1782
EP - 1788
JO - Journal of Immunology
JF - Journal of Immunology
IS - 4
ER -